Association of myeloid-derived suppressor cells with hematopoietic recovery after high-dose chemotherapy in multiple myeloma

Association of myeloid-derived suppressor cells with hematopoietic recovery after high-dose chemotherapy in multiple myeloma

Myeloid-derived suppressor cells (MDSCs) play an important role in the immune response regulation in many pathologies, primarily in malignant tumors, but their role in the hematopoietic stem cell engraftment and the hematopoietic recovery after high-dose chemotherapy and autologous stem cell transpl...

Full description

Bibliographic Details
Main Authors:	V. S. Anmut, T. V. Tyrinova, E. V. Batorov, T. A. Aristova, S. A. Sizikova, G. Yu. Ushakova, V. V. Denisova, E. R. Chernykh
Format:	Article
Language:	Russian
Published:	St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2023-06-01
Series:	Медицинская иммунология
Subjects:	myeloid-derived suppressor cells multiple myeloma transplantation hematopoietic stem cells duration of leukopenia early hematopoietic recovery
Online Access:	https://www.mimmun.ru/mimmun/article/view/2700

Similar Items

Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation
by: Tamara Tyrinova, et al.
Published: (2024-03-01)

Attempt to assess direct interactions between tumor burden, myeloid-derived suppressor cells and PD-1- and TIM-3-expressing T cells in multiple myeloma patients
by: E. V. Batorov, et al.
Published: (2023-06-01)

Myeloid-derived suppressor cells in hematological malignancies: friends or foes
by: Meng Lv, et al.
Published: (2019-10-01)

Tristetraprolin limits age-related expansion of myeloid-derived suppressor cells
by: Kyu Hwan Kwack, et al.
Published: (2022-10-01)

Expansion of myeloid-derived suppressor cells in the peripheral blood of patients with ankylosing spondylitis
by: A. Yu. Morenkova, et al.
Published: (2021-05-01)

Hematopoietic stem cell transplantation in the treatment of multiple myeloma
by: Angelo Maiolino
Published: (2002-01-01)

CLINICAL EFFECTS OF MESENCHYMAL STROMAL CELLS IN LYMPHOMA PATIENTS WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: E. V. Batorov, et al.
Published: (2012-05-01)

Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemia
by: Félicité de Charry, et al.
Published: (2023-01-01)

Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma
by: O S Pokrovskaia, et al.
Published: (2012-07-01)

Myeloid-derived suppressor cells in multiple myeloma patients at the immune recovery and after high-dose chemotherapy and hematopoietic stem cell transplantation
by: T. V. Tyrinova, et al.
Published: (2023-01-01)

Gemfibrozil Induces Anemia, Leukopenia and Reduces Hematopoietic Stem Cells via PPAR-α in Mice
by: Gabriel Rufino Estrela, et al.
Published: (2020-07-01)

Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma
by: Maiia V. Firsova, et al.
Published: (2021-07-01)

The use of non-cryopreserved hematopoietic stem cells for autologous transplantation in multiple myeloma patients
by: S. V. Voloshin, et al.
Published: (2022-04-01)

Differentiation of regulatory myeloid and T-cells from adult human hematopoietic stem cells after allogeneic stimulation
by: James M. Mathew, et al.
Published: (2024-02-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma
by: Mi-Hyun Bae, et al.
Published: (2021-10-01)

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
by: Nitin Sood, et al.
Published: (2023-04-01)

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
by: Claudia Giannotta, et al.
Published: (2023-01-01)

Investigation of the effects of B16F10 derived exosomes in induction of immunosuppressive phenotype in the hematopoietic stem cells
by: M. Atashzar, et al.
Published: (2023-12-01)

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
by: Kharfan-Dabaja Mohamed A, et al.
Published: (2013-01-01)

Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease
by: M V Solovyev, et al.
Published: (2017-07-01)

Transcription of <i>WNT</i> Genes in Hematopoietic Niche’s Mesenchymal Stem Cells in Multiple Myeloma Patients with Different Responses to Treatment
by: Natella I. Enukashvily, et al.
Published: (2023-05-01)

Myeloid derived suppressor cells as therapeutic target in hematological malignancies
by: Kim eDe Veirman, et al.
Published: (2014-12-01)

Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation
by: Lisha Ai, et al.
Published: (2019-04-01)

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation
by: Sung-Eun Lee, et al.
Published: (2019-02-01)

Editorial: Characteristics and behaviors of hematopoietic stem cells and leukemia stem cells in hematologic malignancies
by: Haojian Zhang, et al.
Published: (2022-10-01)

Hematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction
by: Geoffrey Brown
Published: (2022-11-01)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
by: Rong Fan, et al.
Published: (2022-10-01)

THE COMPARATIVE ANALYSIS OF GRAFT CELL SUBTYPES AND ITS CYTOKINE PRODUCTION OF LYMPHOMA AND LEUCOSIS PATIENTS
by: D. S. Baranova, et al.
Published: (2012-05-01)

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
by: Nikita E. Mochkin, et al.
Published: (2020-07-01)

THE EFFICACY OF HIGH-DOSE CONSOLIDATION AND AUTOLOGOUS BONE MARROW TRANSPLANTATION IN FIRST REMISSION OF ACUTE MYELOID LEUKEMIA
by: I. A. Samorodova, et al.
Published: (2018-05-01)

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion
by: Shohei Mizuno, et al.
Published: (2024-04-01)

Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
by: M. Ryan Corces, et al.
Published: (2017-11-01)

Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Katie Culos, et al.
Published: (2019-05-01)

Mobilization of hematopoietic stem cells (HSCs) by using Pleriksafor (Mozobail) in combinationwith colony-stimulating factor in patients with previous failure transplant procurement for autotransplantation of HSCs
by: N B Mikhailova, et al.
Published: (2014-03-01)

Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients
by: M. V. Solovev, et al.
Published: (2019-01-01)

Hematopoietic–Mesenchymal Signals Regulate the Properties of Mesenchymal Stem Cells
by: Sanshiro Kanazawa, et al.
Published: (2022-07-01)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
by: Rafiye Çiftçiler, et al.
Published: (2019-05-01)

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
by: Zhaonian Hao, et al.
Published: (2021-10-01)